

Professor Thomas Powles



Research Interests

My research interest is genitourinary cancer (GU) cancer. These include clinical studies from phase I to randomised phase III trials, the majority being translational phase II studies investigating novel targeted and immune therapies.

I also lead a c biomarker team which aims to identify markers that are of prognostic value and can predict response or resistance to targeted therapy.

- HER 1-4, PDL-1, FGF-2 and Src as markers in bladder and renal cancer.

Major Funders

- Cancer Research UK
- Medical Research Council

Contact Details

Email: thomas.powles@bartshealth.nhs.uk



Professor Thomas Powles



Recent Publications

- Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, Nathan P, Wilson P, Shamash J, Sharpe K, Lim L, Dickson J, Ell P, Reynolds A, **Powles T**. *Clin Cancer Res* 2011 Sep 15; 17(18): 6021-8
- The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. **Powles T**, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O'Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A. *Eur Urol* 2011 Sep; 60(3): 448-54
- Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. Lorch A, Bascoul-Mollevis C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin K, Lotz JP, Germà-Lluch JR, **Powles T**, Kollmannsberger C, Beyer J. *J Clin Oncol* 2011 Jun 1; 29(16): 2178-84.
- Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib. **Powles T**, Chowdhury S, Shamash J, Bazeos A, Gillessen S, Saunders N, Lim L, Sarwar N, Sadev A, Wilson P, Nathan P, Boleti K, Peters J, Agrawal S. *Ann Oncol* 2011 Apr; 22(4): 815-20.
- A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP. Perry J, Ghazaly E, Kitromilidou C, McGrowder EH, Joel S, **Powles T**. *Mol Cancer Ther* 2010 Dec; 9(12): 3322-9